急性冠脉综合征患者经替格瑞洛治疗后血栓弹力图的变化  

Change of thrombelastogram in acute coronary syndrome patients treated by ticagrelor

作　　者：杨葳[1] 柯丹[1] 曾国彬[1] 

机构地区：[1]武警福建总队医院,350003

出　　处：《中国实用医药》2014年第33期30-32,共3页China Practical Medicine

摘　　要：目的研究急性冠脉综合征(ACS)患者经替格瑞洛治疗前后血栓弹力图(TEG)的变化特点。方法 89例ACS患者给予替格瑞洛抗血小板治疗1周前后,抽血查血栓弹力图,比较其前后变化特点。结果替格瑞洛治疗后1周较治疗前TEG指标均有所改善,主要表现为R、K值升高,MA值、α角和G值、CI减小,但差异均无统计学意义(P>0.05)。但AA途径、ADP受体途径的抑制率均有所升高,且与治疗前相比差异有统计学意义(P<0.01)。结论替格瑞洛是一种很有前景的抗血小板药物,可以适应ACS及介入术后患者个体化治疗的需要,使血小板抑制率达标,最终使更多患者获益。Objective To research the change characteristics of thrombelastogram（TEG） in acute coronary syndrome（ACS） patients treated by ticagrelor. Methods A total of 89 ACS cases were treated by ticagrelor antiplatelet therapy for 1 week, The characteristics of thrombelastogram before and after treatment were compared. Results Compared with the index before treatment, the TEG index of ACS patients improved after ticagrelor treatment, such as increased R and K, and decreased MA, α-angle, G, and CI, but the differences had no statistical significance（P〉0.05）. Inhibiting rates through AA-passage and ADP receptor-passage were increased, and the difference had statistical significance, compared with that before treatment（P〉0.01）. Conclusion Ticagrelor is a promising anti-platelet drug and it is adaptable to individuation treatment of patients with ACS and interventional therapy. It can make inhibiting rate of platelet reach the standard and benefit patients.

关 键 词：急性冠脉综合征 替格瑞洛 血栓弹力图 

分 类 号：R541.4[医药卫生—心血管疾病]